Levosimendan Administration and Outcome in Cardiac Surgery

Charite University, Berlin, Germany159 enrolled

Overview

To assess the effects on outcome of levosimendan with respect to timing of its administration on the postoperative course of high-risk cardiac surgery patients in a retrospective observational study.

Study Type

OBSERVATIONAL

Enrollment

159

Conditions

Treatment of Left Heart Insufficiency in an Operative Setting of Cardiac Surgery

Interventions

LevosimendanDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients undergoing cardiac surgery between 2006 and 2013 * levosimendan administration within 24 hours of postoperative ICU admission Exclusion Criteria: * patients younger than 18

Locations (1)

Charité University Medicine

Berlin, State of Berlin, Germany

Outcomes

Primary Outcomes

In-hospital mortality

Time frame: until discharge, an average of 3 weeks length of stay

1 year follow-up mortality

Time frame: 1 year after surgery

Secondary Outcomes

Duration of mechanical ventilation

Time frame: until discharge, an average of 3 weeks length of stay

Incidence of renal dysfunction

Time frame: until discharge, an average of 3 weeks length of stay

Incidence of renal replacement therapy

Time frame: until discharge, an average of 3 weeks length of stay

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.